Digest Network Come funziona
Network
/
Società
Mi
Non verificato

Mirum Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieMercato azionarioSalute

81 comunicati stampa

Guarda tutti i comunicati
11/06/2026
Mercato azionario
Finanza
Biotecnologia
Farmaceutica
Salute
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
30/05/2026
Eventi
Industria
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
21/05/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
14/05/2026
Mercato azionario
Finanza
Biotecnologia
Farmaceutica
Salute
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
13/05/2026
Titoli e azioni
Finanza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
12/05/2026
Titoli e azioni
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
12/05/2026
Web e Social Network
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
06/05/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/05/2026
Fiere
Eventi
Industria
Web e Social Network
Telefonia e Varie
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
03/05/2026
Telefonia e Varie
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
Fonte
Mirum Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0